Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
- The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable systemic delivery of oligonucleotide therapies across the blood-brain barrier
- This collaboration marks a strategic step for both companies in expanding their presence in targeted delivery and CNS indications, uniting complementary expertise in RNA therapeutics and advanced delivery technologies
- This strategic agreement unlocks new potential treatments for neurodegenerative and other CNS disorders and delivering solutions that truly impact patient lives
Martinsried, Germany, and Marseille, France, July 10, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, today announced that the companies have entered into a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS).
Secarna Pharmaceuticals to present new data and clinical strategy for lead antisense oligonucleotide program SECN-15 at ASCO 2025
- Data support that targeting NRP1 with antisense oligonucleotides is a promising therapeutic strategy for solid cancers where current immunotherapies show limited benefit
- SECN-15 demonstrates meaningful anti-tumor activity as well as excellent safety and tolerability profile in vivo
- Gastric cancer selected as a lead indication for planned Phase I/II clinical trial
Martinsried (Munich), Germany, May 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, will present new data on the company’s lead program, SECN-15, a potential first-in-class antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 4 in Chicago, Illinois, USA.
Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement
Martinsried (Munich), Germany, May 12, 2025 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced the signing of a research and option agreement for a scientific and strategic collaboration with one of Curie.Bio’s portfolio companies.
Latest News & Events
Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
- The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable systemic delivery of oligonucleotide therapies across the blood-brain barrier
- This collaboration marks a strategic step for both companies in expanding their presence in targeted delivery and CNS indications, uniting complementary expertise in RNA therapeutics and advanced delivery technologies
- This strategic agreement unlocks new potential treatments for neurodegenerative and other CNS disorders and delivering solutions that truly impact patient lives
Martinsried, Germany, and Marseille, France, July 10, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, today announced that the companies have entered into a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS).
Secarna Pharmaceuticals to present new data and clinical strategy for lead antisense oligonucleotide program SECN-15 at ASCO 2025
- Data support that targeting NRP1 with antisense oligonucleotides is a promising therapeutic strategy for solid cancers where current immunotherapies show limited benefit
- SECN-15 demonstrates meaningful anti-tumor activity as well as excellent safety and tolerability profile in vivo
- Gastric cancer selected as a lead indication for planned Phase I/II clinical trial
Martinsried (Munich), Germany, May 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, will present new data on the company’s lead program, SECN-15, a potential first-in-class antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 4 in Chicago, Illinois, USA.
Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement
Martinsried (Munich), Germany, May 12, 2025 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced the signing of a research and option agreement for a scientific and strategic collaboration with one of Curie.Bio’s portfolio companies.